

Daniela Mauer, Carola Barth, Katharina Drechsel, Constanze Radek, Ian C. D. Johnston, Stefan Wild, Sabrina Schmitz, Carolin Kolbe, Mario Assenmacher, Andrew D. M. Kaiser, and Nadine Mockel-Tenbrinck  
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany

## Introduction

The clinical success of adoptive T cell transfer therapy is resulting in growing enthusiasm as indicated by the ever-increasing number of clinical trials and the involvement of large pharmaceutical companies.

Aiming to streamline the safe and robust clinical manufacturing of gene-engineered T cells, we have developed a cGMP-compliant stimulation reagent, MACS<sup>®</sup> GMP T Cell TransAct™. This reagent enables potent polyclonal T cell activation prior to gene modification (lenti- and retroviral) in the absence of feeder cells and can be easily integrated into a closed manufacturing process such as the TCT Process on the

CliniMACS Prodigy<sup>®</sup>. MACS GMP T Cell TransAct is a soluble polymeric nanomatrix conjugated to humanized CD3 and CD28 agonists. It can be sterile-filtered and is biodegradable. In contrast to the large beads previously used in the field, MACS GMP T Cell TransAct presents several advantages: “de-beading” steps are no longer required resulting in simplification of the manufacturing process. Moreover, as the reagent is soluble, there is no more critical dependence on a bead-to-cell ratio, thus enabling more reliable and flexible conditions for the stimulation of T cells over a large range of T cell densities.

## Results

### 1 TransAct™ T Cell Reagent enables potent T cell stimulation, proliferation, and expansion in research settings




Figure 1

Pan T cells were stimulated with TransAct T Cell Reagent or three different products from other manufacturers (reagents A, B, C). Activation was assessed by measuring expression of the activation markers CD25 and CD69 on day 2 (fig. 1A). On day 6, proliferation was analyzed by CFSE dilution assay (fig. 1B). Lentiviral gene expression, i.e., transduction efficiency,

after polyclonal stimulation was evaluated on day 7 (fig. 1C). Expansion was analyzed at the indicated time points for T cells cultured in serum-free conditions (TexMACS™ Medium) or RPMI + 10% FCS (fig. 1D). All cultivation steps took place in 96-well culture dishes. Data represent the average from two experiments, each in triplicate, with T cells from two donors.

### 2 Clinical-scale manufacturing of gene-modified T cells




Figure 2

#### Automated polyclonal T cell stimulation

For evaluation of clinical-scale manufacturing, CD4<sup>+</sup>/CD8<sup>+</sup> T cells were enriched from a blood sample, subsequently cultured in TexMACS GMP Medium supplemented with IL-7 and IL-15, and activated using MACS GMP T Cell TransAct. The entire

process was performed automatically in the CliniMACS Prodigy (fig. 2). Pictures were taken with the integrated microscope camera of the CliniMACS Prodigy, 24, 48, and 72 hours after stimulation (fig. 3).




Figure 3

#### Generic manufacturing of CAR T cells

Enriched CD4<sup>+</sup>/CD8<sup>+</sup> T cells were subjected to polyclonal stimulation with MACS GMP T Cell TransAct, transduced with lentiviral vectors, and expanded in TexMACS GMP Medium supplemented with IL-7 and IL-15 (n = 11). All steps were performed

using the standard TCT Process (fig. 2) on the CliniMACS Prodigy. The T cell culture was monitored at different time points to determine cell viability (fig. 4A). The absolute cell count of viable cells over time was calculated (fig. 4B).




Figure 4

#### Lenti- or retroviral modification after polyclonal activation

T cells were enriched using CliniMACS CD4 and CD8 Reagents and stimulated with MACS GMP T Cell TransAct. Polyclonally activated T cells were modified using lentiviral or retroviral constructs encoding GFP or CAR. The complete process to

generate genetically engineered T cells was performed in a single closed platform, the CliniMACS Prodigy and Tubing Set TS 520. The transduction efficiency was determined six days after transduction (fig. 5).




Figure 5

### 3 High-efficiency transfection of human T cells using electroporation

T cells were enriched using CliniMACS CD4 and CD8 Reagents, stimulated with TransAct T Cell Reagent, and transfected with plasmid DNA or RNA, both encoding GFP, three days after activation. Transfection was performed using the electroporation

platform of the CliniMACS Prodigy. The transfection efficiency was assessed by flow cytometry (MACSQuant<sup>®</sup> Analyzer 10) 24 hours after electroporation.




Figure 6

## Conclusion

- MACS GMP T Cell TransAct enables potent and robust T cell activation.
- The reagent can be used in combination with the commercially available TCT Process on the CliniMACS Prodigy.
- The automated process for manufacturing gene-modified T cells yields a consistent cell product for the development of adoptive T cell therapies.

**Funding:** This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 667980.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS<sup>®</sup> GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS<sup>®</sup> System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485. In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC (“human tissues and cells”), or the Directive 2002/98/EC (“human blood and blood components”) – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System. In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. In the US, the CliniMACS Prodigy<sup>®</sup> T Cell Transduction Process is available for research use only. CliniMACS, CliniMACS Prodigy, MACS, the MACS logo, MACSQuant, TexMACS, and TransAct are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. Copyright © 2017 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.